Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Conditions
- Chronic Myelomonocytic Leukemia
- de Novo Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome
- Refractory Anemia With Excess Blasts in Transformation
- Secondary Myelodysplastic Syndrome
Interventions
- DRUG: Azacitidine
- DRUG: Ibrutinib
Sponsor
Brian Jonas
Collaborators